-
My mother inspired a generation with her fight against breast cancer before dying at 43... 16 years later, I've discovered I have the same gene that led to her death. This is the test all women must take
15 Jan 2026 19:35 GMT
… BRCA genes linked to breast cancer.
Jane was never … of ovarian cancer and breast cancer significantly.
When a child … drugs such as tamoxifen, Arimidex and letrozole – particularly for … major risk reduction against breast cancer’.
Becca quickly decided that …
-
Cardiovascular Risks of Aromatase Inhibitors versus Tamoxifen in Postmenopausal Breast Cancer: A Multinational Cohort Study
13 Jan 2026 09:36 GMT
… approximately 4% received anastrozole, 1% exemestane, … inhibitors in breast cancer patients. Clin Breast Cancer. 2017 … thromboembolism in breast cancer survivors. Breast Cancer Res Treat. … breast cancer patients receiving adjuvant tamoxifen. Breast Cancer Res …
-
Breast cancer death rates plummet to new low in UK thanks to early diagnosis and better treatments
26 Dec 2025 22:34 GMT
… , experts say.
But breast cancer remains the second biggest … and increases survival chances.
Breast cancer remains the second biggest … to this.
'Breast cancer screening is more accurate … year. Drugs like tamoxifen, anastrozole and Herceptin, developed with …
-
<![CDATA[Palazestrant Monotherapy Moves Into Phase 3 Examination in ER+, HER2– Breast Cancer]]>
25 Dec 2025 17:44 GMT
… IN ER+, HER2– BREAST CANCER
Palazestrant monotherapy was previously … advanced or metastatic breast cancer with measurable disease … subsequent cycle, oral anastrozole at 1 mg once … metastatic breast cancer: phase 1/2 study results. Breast Cancer Res …
-
Management Strategies and Outcomes in HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies
23 Dec 2025 18:34 GMT
… and phenotypic evolution. Breast cancers can alter their receptor … anastrozole 1 mg for hormone receptor-positive advanced breast cancer … therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5 … +/HER2- breast cancer. Clin Breast Cancer. 2020;20(1 …
-
<![CDATA[1L Giredestrant Yields Improved IDFS vs ET in ER+/HER2– Breast Cancer]]>
18 Dec 2025 20:29 GMT
… SOC endocrine therapy with tamoxifen, anastrozole, letrozole, or exemestane.
The … IDFS excluding second primary non-breast cancer. Secondary end points included … III lidERA Breast Cancer trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December …
-
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
18 Dec 2025 00:57 GMT
… breast cancer.
The global market for HER2-negative breast cancer … breast cancer patients that are resistant to breast cancer … (HR+HER2-) breast cancer, neoadjuvant hormone therapy … treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or …
-
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
12 Dec 2025 17:16 GMT
… /Advanced Breast Cancer
Metastatic/advanced breast cancer (ABC) is … cases of breast cancer diagnosed in 2024. Breast cancer is the … certain HR+, HER2- breast cancers in the adjuvant and … Verzenio plus anastrozole or letrozole vs anastrozole or letrozole, …
-
<![CDATA[Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer]]>
10 Dec 2025 22:50 GMT
… SOC endocrine therapy with tamoxifen, anastrozole, letrozole, or exemestane.
The … IDFS excluding second primary non-breast cancer. Secondary end points included … III lidERA Breast Cancer trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December …
-
Giredestrant potential new standard in early breast cancer
10 Dec 2025 21:38 GMT
… during the San Antonio Breast Cancer Symposium.
Aditya Bardia
“ER … HER2-negative breast cancer accounts for the majority of early breast cancers, with … tamoxifen, letrozole (Femara, Novartis), anastrozole (Arimidex, Ani Pharmaceuticals) or exemestane ( …
About
© 1995-2026